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Global Responses: The Search for Cures in the
Development of Pharmaceuticals
STUART R. WALKER*
In this article, Professor Stuart Walker examines several challenges that
will be faced by the global pharmaceutical industry in the near future. These
involve the question of improving the overall quality of life and care for
millions in an era of cost containment. In order to respond to the increasing
demands for advances in medicine while simultaneously retaining an
industrially strong, innovative, and resilient economy, responsibility for the
necessary changes will need to be shared among governments, the
pharmaceutical industry, and health care professionals.
Inparticular,four challengesfacedby the global pharmaceutical industry
and their responses to each are discussed The first of these is the needfor the
industry to secure sufficient revenue from marketed products, so that they may
both remain profitable and be able to invest in research and development to
facilitate the creation of new medicines. The second challenge arises out of
that research and development and involves the production of innovative
medicines for the treatment or prevention of diseases for which there is no
adequate treatment. Once these new medicines are developed, the third
challenge faced by the industry is to bring the new medicines to market in a
more rapid and efficient manner. Achieving this third goal is closely
intertwined with the final challenge: restructuring the regulation ofimedicines
to ensure the rapid review of new drug applications to get these new medicines
to market. Although much remains to be done in achieving these goals,
Professor Walker notes that the global pharmaceutical industry is taking
decisive steps to approach these challenges and his article operates as a
framework for continued progression.
* Director, Centre for Medicines Research International; Honorary Professor of Pharmaceutical
Medicine, University of Wales, Cardiff.
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INTRODUCTION
As we approach the new millennium, several global challenges need to be
addressed. For example, a number of diseases have either no treatment or
inadequate therapies. The World Health Organization's objective of "Health
for All by the Year 2000" remains a distant dream, and the overall quality of
life and quality of care for the millions of sufferers in the world in an era of
cost containment will prove difficult. Commentators have recently stated that
the post-millennial economy must be industrially strong, innovative, and
resilient in order to respond to the increasing demand for advances in
medicines and better health care.' The establishment of such capabilities
requires that responsibility be shared among governments, the pharmaceutical
industry, and health care professionals. In particular, the global
pharmaceutical industry faces four basic challenges; namely to remain
profitable, to carry out innovative discovery research, to bring new medicines
more quickly to the market place, and to ensure that the drug review process
is both rapid and efficient. In this article, I review each of these four
challenges, discuss the responses of the global pharmaceutical industry to
these challenges, and present data to illustrate the outcomes achieved in the
pharmaceutical industry to date.
I. THE PROFIT CHALLENGE
A major challenge for the global pharmaceutical industry is to secure
sufficient revenue from marketed products. This involves appropriate
investment in research and development (R&D) to ensure the continuous
creation of new medicines. This revenue challenge looms large because the
expansion of the global pharmaceutical market has slowed down. While
global pharmaceutical sales increased annually in the 1980s by double digit
figures, as Figure 1 demonstrates, the IMS Strategy Group predicts that sales
growth in the latter 1990s will be near seven percent. The estimated global
market in 1996 was approximately $296 billion, with an average of fifteen
percent of sales being invested by pharmaceutical companies in R&D. Over
the past two decades, R&D investment in the pharmaceutical industry has
I. Pharmna Poltics 2000-Key Issues for the Industry: Heinz Redwood Report (1997) (on file with
author).
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doubled every five years from $5.5 billion in 1981 to $45 billion in 1996. The
question that needs to be addressed is whether this level of R&D expenditure
can continue without an adequate return on the investment. Currently, to get
an appropriate price agreement or to make sure that a product is included on
a formulary, companies have to not only establish the quality, safety, and
efficacy of their products, but also determine the cost-benefit, cost-
effectiveness, or the cost-utility of the medicines to be prescribed.
In an era where health care costs are rising because of demand for the
highest quality care, the increasing cost of innovative technologies, an ever
expanding aging population, and a key interest in assessing patients' quality
of life, a large number of government initiatives have been designed to curtail
health care expenditures. These initiatives put pressure on prescribers to
prescribe generically or less costly innovative medicines, to shift costs to
patients by instituting co-payment plans, and to put downward pressure on
prices or the profitability of the pharmaceutical industry. The industry's
response to these changes has been to: restructure in terms of cost cutting and
downsizing, reengineer the drug development process, pursue horizontal
integration, and refocus by reexamining the industry's role in the health care
delivery system. Health economic studies are just one of the practical aids in
decision making and drug selection as purchasers and prescribers endeavor to
evaluate "value for money" in health care. Such cost-containment measures
directly affect the revenue expectations in the pharmaceutical industry.
Mergers and acquisitions within the global pharmaceutical industry have
developed as one of the major responses to the challenge to remain profitable.
The 1997 Heinz Redwood report described the mergers and acquisitions of the
1990s as a continuation of the gradual concentration of the research-based
pharmaceutical industry that has occurred in periodic bursts ever since the
restructuring in 1970 when Ciba merged with Geigy, Warner Lambert acquired
Parke Davis, and the Schering Corporation merged with Plough.2 The next
concentrated burst of mergers did not occur until nearly twenty years later in
1989-91, with the mega-mergers of Bristol Myers and Squibb, SmithKline and
Beecham, as well as those between Novo and Nordisk, Rhone Poulenc and
Rorer, and Sanofi and Sterling Drug. After a brief period of relative calm on
the merger front, feverish activity resumed during 1994-96 involving the
merger of Glaxo and Wellcome, and Pharmacia and Upjohn, and the formations
2. Id.
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of Hoechst Marion Roussel and Novartis (Sandoz and Ciba). In addition, there
were significant acquisitions by Roche (of Syntex), American Home Products
(of American Cyanamid), Rhone-Poulenc Rorer (of Fisons), and BASF (of
Boots Pharmaceutical Division). The most powerful motive of the frequent
merger activity in the global pharmaceutical industry in the 1990s has been cost
reduction. With slower market growth combined with vigorous cost-
containment efforts in health care systems and high levels of R&D
expenditures, a competitive premium has been placed on a pharmaceutical
company's ability to reduce costs to maintain adequate profitability. Horizontal
integration has proved a popular organizational strategy to reduce costs in the
pharmaceutical industry.
Vertical integration has been another response of the pharmaceutical
industry to the pressure to contain costs. Vertical strategies can involve
backward integration into pharmaceutical chemicals, or forward integration into
wholesaling or retail distribution of drugs. In the 1990s, however, vertical
integration acquired a new meaning; namely the participation of research-based
pharmaceutical companies in health care activities. This participation took the
form of alliances created when leading research-based pharmaceutical
companies, particularly in the United States, purchased Pharmacy Benefit
Managers (PBMs) in order to gain experience in prescription management and
access to prescription management data. By moving into PBMs,
pharmaceutical companies gain "in-house" access to prescription data that will
help them to develop disease management schemes 3 A combination of drug
expertise, product development, direct insight into the management of cost
containment, and detailed knowledge of prescribing habits and health outcomes
should result in integrated pharmaceutical care, which could ultimately benefit
patients. In producing horizontal and vertical integration in the global
pharmaceutical industry, the pressure of cost containment has led
pharmaceutical companies to think and act in new ways to meet the profit
challenge. In so thinking and acting, pharmaceutical companies are becoming
more keenly aware of the dynamics of health economics, particularly how
medicines affect the cost of integrated health care systems that are increasingly
cost conscious.
3. Id.
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II. THE INNOVATION CHALLENGE
The second challenge facing the global pharmaceutical industry is to
produce innovative medicines for the alleviation, treatment, prevention, or cure
of diseases for which there is either no treatment or inadequate treatment
available. The research-based pharmaceutical industry's innovative capacity
remains its most important attribute. Professor Jurgen Drews, President of
International R&D with Hofflnann-La Roche, recently stated that "the most
critical factor determining the survival and success of the pharmaceutical
industry is its ability to provide novel and economically feasible medicines for
the alleviation or cure of serious diseases."4  The Centre for Medicines
Research International (CMR International) has established a marketed
medicines database that documents all new chemical entities that have come
into the world market over the past twenty-five years. While this database only
details new chemical entities, without making any judgment with regard to their
innovative value, it does highlight the fact that the global pharmaceutical
industry has marketed forty to fifty new molecular entities each year since the
early 1970s, giving a total output between 1970 and 1996 of almost 1,300
compounds. As Figure 2 shows, the data suggests that the total numbers have
been declining in the past decade, however, there are strong indications that the
pharmaceutical industry intends to remain at the cutting edge of innovative
research. For example, pharmaceutical companies are examining new and
better ways of improving the drug discovery process by means of combinatorial
chemistry and high throughput screening, as well as actively exploring new
medical treatments including genetic manipulation and gene therapy.' In
addition, the discarding of the "not invented here" syndrome means that there
is a keen interest in forming alliances and collaborations with government
organizations and academic institutes. There is also an interest in forming
alliances with inter-company collaborations such as those developed in the
1990s in the field of AIDS research and those starting to develop in connection
with malaria.
An examination of the various databases that identify and document the
numerous products in the pipeline allows one to refute the critics of the
4. Jurgen Drews, The Impact of Cost Containment on Pharmaceutical R&D, Centre for Medicines
Research International Annual Lecture (1995).
5. Richard Sykes, The Pharmaceutical Industry in the New Millennium: Capturing the Scientific
Promise, Centre for Medicines Research International Annual Lecture (1997).
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pharmaceutical industry who would like to imply that there is a concentration
of resources and investment in a limited number of therapeutic areas. Since
1980, major advances have occurred in (1) cardiovascular therapy: ACE
inhibitors and lipid lowering agents; (2) nervous system drugs: SSRI
antidepressants, anti-migraine treatments, and major improvements in
anaesthetics and anti-epileptics; (3) anti-cancer drugs: new products that
significantly improve the chances of survival in several types of cancer and
anti-emetics diminishing the problems of nausea and vomiting in
chemotherapy; (4) anti-infective drugs: including drugs to combat IIV
infection in AIDS, other anti-virals, and new antibiotics with greater
effectiveness in treating difficult or resistant bacteria; (5) gastro-intestinal
drugs: protein pump inhibitors, systemic anti-fungals, and drugs to avert the
rejection of transplanted organs; and (6) the first important drugs from
biotechnology and genetic engineering: erythropoietins, TPA, human growth
hormones, colony stimulating factors, monoclonal antibodies, and others.
Several studies have endeavored to assess the innovative value of new
products introduced into the world market but have failed in their methodology
by limiting the assessment of innovation to chemical structure and clinical
value. In order to appropriately describe the novelty of such medicines, one
needs to take into account not only chemical structure, which perhaps is of least
importance, but also the pharmacological mode of action, whether the medicine-
introduces a new therapeutic concept, its clinical value, whether it has an
improved safety profile, and its socioeconomic benefit. Surrogate markers,
such as whether the product is internationalized (on the major world markets
including the United States, Europe, and Japan) and its sales value, might also
be considered when examining innovative value. While the global
pharmaceutical industry has continued to demonstrate innovative capacity as
the pressure of cost containment has taken hold in the pharmaceutical and
health care sectors, future innovations will depend on the pharmaceutical
industry's success in continuing to meet the profit challenge. As noted earlier,
high levels of R&D expenditure cannot continue without an adequate return on
R&D investment. Pressure to continue to reduce costs will place disciplines on
R&D that might reduce the scope for drug innovations; but it will be innovative
medicines that provide the biggest boost to pharmaceutical companies in their
attempts to generate sufficient revenue for R&D and profits. The first two
challenges for the global pharmaceutical industry-the profit and innovation
challenges-are interdependent in that one cannot be successfully handled unless
both are.
[Vol. 5:65
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III. THE EFFICIENCY CHALLENGE
The third challenge to the global pharmaceutical industry is to bring new
medicines more quickly and efficiently to the marketplace for the benefit of
society. CMR International's database of marketed medicines allows drug
development time, defined as time from synthesis to the first marketing of the
drug, to be examined over the past thirty years. In the early 1960s,
development time was approximately two to three years [Figure 3]. By the
early 1990s, development time had extended to approximately twelve years.
However, over the past decade, development time has remained remarkably
constant at between ten and twelve years, with some evidence that this has now
started to decrease. There is widespread sentiment in the pharmaceutical
industry that a ten to twelve year development time is too long and has to be
shortened. Industry's response to this challenge is to set its target at around six
to eight years, with an average of three years for the pre-clinical phase and an
additional four years for clinical development of the drug.
In order to effectively reduce drug development times, pharmaceutical
companies are looking at ways to reengineer the drug development process.
Critical to reducing drug development time is the establishment of a
benchmarking program to determine where time is lost and how the process can
be speeded up and made more efficient. CMR International has established an
on-going major benchmarking exercise that currently has the support of forty
leading pharmaceutical companies, including seventeen out of the top twenty
in the world. As demonstrated in Figures 4 and 5, this program has allowed the
identification of "macro" benchmarks such as: first synthesis, first
administration to man, first dose to patients for target indication, first dose in
the first pivotal safety and efficacy trial, submission of first drug registration
dossier, first launch in first market, and the subsequent launches into the top ten
major markets for pharmaceutical products.
In addition, CMR International has defined "micro" benchmarks for the
clinical development period. As seen in Figure 6, these include: protocol
initiation to protocol approval, first patient to last patient enrolled, first dose to
first patient to last patient last visit, last patient to database lock, and from
database lock to approved report. These data are now being collected on a
yearly basis, and the baseline data for over 300 new chemical entities
investigated and 350 clinical studies conducted during the period 1994-95 have
allowed for the establishment of a valuable database. Data will continue to be
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collected on a yearly basis and will permit the critical analysis of drug
development times. This will allow pharmaceutical companies to share
successful practices and the subsequent improvements in their time-lines. An
example of such a time line is shown in Figure 7.
Nearly fifty years ago, Joseph Schumpeter stated that innovation has two
components: the generation of novelty and the maintenance of novelty. The
first component is achieved by discovery, dependent on the most intelligent and
creative use of science. The second part of innovation is achieved by
development and is based on process knowledge, logistics, and organization.6
The challenge of bringing new medicines to market more quickly and
efficiently will depend on the global pharmaceutical industry's success in
improving the product development process through better knowledge of the
process, more efficient logistics, and organization. Macro and micro
benchmarks, such as those developed by CMR International, demonstrate that
the development process can be reorganized to enhance efficiency.
Schumpeter's two part definition of innovation also suggests that the efficiency
challenge directly connects with the innovation challenge facing the global
pharmaceutical industry. In addition, efficiency serves pharmaceutical
companies well as they attempt to meet the profit challenge in the era of cost
containment. Again, the challenges facing the global pharmaceutical industry
are interdependent and must be approached as such by pharmaceutical
companies.
IV. THE REGULATORY CHALLENGE
The final challenge to the global pharmaceutical industry is for
governments to ensure an efficient and rapid review of new drug applications
to allow innovative medicines access to the major markets. The introduction
of regulatory requirements by the major governments of the world to ensure
appropriate quality, safety, and efficacy of new medicines undoubtedly had a
significant impact on overall drug development times by creating the need for
a regulatory review process.
In the 1960s and 1970s, the regulatory review process for new drugs
usually took only a few months. The development of increasingly complex and
demanding regulatory procedures significantly lengthened the review process
6. 1 JOSEPH A. SCHuMPETER, BusINEss CYCLES 87-192 (1939).
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so that in some countries the process could take three to four years. Given the
absence of any centralized regulatory review process internationally,
pharmaceutical companies were facing longer and longer regulatory review
processes in all major pharmaceutical markets. As demonstrated by Figure 8,
in the past decade, the data indicates that, in general, regulatory review times
in different countries have decreased; but the median review time in nine major
countries still remains between one and two and a half years.
To achieve the objective of a six month review period, two strategies are
essential: (1) intergovernmental efforts at pharmaceutical regulatory
harmonization through the International Conference of Harmonization (ICH)
should be continued; and (2) partnerships between global pharmaceutical
companies and national regulatory authorities should be formed to identify
ways to streamline the review process without sacrificing necessary regulatory
oversight. A recent initiative along the lines of industry-government
collaboration is the identification of key milestones in the regulatory review
processes of different countries, as shown in Figure 9, and the examination of
the targets set by government authorities and the problems experienced in
meeting the targets.' This type of collaborative study of the regulatory review
process can help produce "good regulatory practices" to parallel "good
laboratory practices" in the industry. Further, this approach can be used in
many different countries, thus contributing to the goal of regulatory
harmonization. Reengineering the drug review process to meet the regulatory
challenge will also need to involve improving transparency, setting clear
performance targets, assuring a consistent quality review, and reducing the
information burdens the regulatory process places on pharmaceutical
companies. The successful implementation of these ideas will require an
improved dialogue between governments through mechanisms like the ICH and
between regulatory authorities and the pharmaceutical companies.
The interdependence of the challenges facing the global pharmaceutical
industry is also apparent when considering the regulatory challenge. A
successful reengineering of the regulatory review processes in major
pharmaceutical markets will help companies deal with the pressure of cost
containment, remove regulatory drag on innovation, and support getting drugs
to market more efficiently.
7. See generallyCENTRE FORMEDICINES RESEARCH INTERNATIONAL, IMPROVINGTHEREGULATORY
REVIEW PROCESS: ASSESSING PERFORMANCE AND SETTING TARGETS, 1997 CMR INTERNATIONAL
WORKSHOP (J.A.N. McAuslane & S.R. Walker eds., 1997).
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CONCLUSION
As we approach the new millennium facing many serious global challenges
to public health and health care systems, the global pharmaceutical industry-as
the main engine in the search for medicines to deal with infectious and chronic
diseases-will play a central role in shaping responses to global health
challenges. The four main challenges confronting the global pharmaceutical
industry today-profit, innovation, efficiency, and regulatory challenges-are
important, not only individually, but also as an interdependent set of challenges
that must be addressed comprehensively. It is my experience that the global
pharmaceutical industry is taking decisive steps to approach the challenges
comprehensively, although much remains to be done. While my focus has been
on the global pharmaceutical industry, it is important to remember that this
industry does not alone bear responsibility for resolving the serious public
health and health care problems present in many countries. Success by the
global pharmaceutical industry in remaining profitable, enhancing innovation,
improving efficiency, and helping regulatory reform is a necessary, but not
sufficient, response to the health concerns facing humanity in the global era.
1997]

